Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Monday that it has reached a settlement with Teva Pharmaceuticals USA Inc (Teva) on the US patent litigation case for Victoza (liraglutide).
As a result of this settlement, Teva is licensed to launch a generic version of Victoza as of 22 December 2023.
Under certain circumstances, Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza® on the market.
In the event that Novo Nordisk is granted six months paediatric extension for Victoza, all these above-mentioned timelines will be extended by six months.
All other terms of the agreement are confidential.
This agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval